Antipsychotic switching in schizoaffective disorder: A systematic review

References

• Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, et al. 2009. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 24(5):229–238.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association, 1994. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: APA.
   Google Scholar
• American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC: APA.
   Google Scholar
• Barak Y, Aizenberg D. 2011. Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia. J Obes 2011 pii: 898013. doi:10.1155/2011/898013.
   PubMedGoogle Scholar
• Bauer M, Glenn T, Grof P, Marsh W, Sagduyu K, Alda M, et al. 2010. The association between concurrent psychotropic medications and self-reported adherence with taking a mood stabilizer in bipolar disorder. Hum Psychopharmacol 25(1):47–54.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Vieta E, Saiz-Ruiz J, Rico-Villademoros F, Alamo C, Bobes J.; Grupo RECAP. 2011. Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Rev Psiquiatr Salud Ment 4(3):150–168.
   PubMed Web of Science ®Google Scholar
• Buckley PF. 2007. Introduction: the art and science of switching antipsychotic medications. J Clin Psychiatry 68(Suppl 6):4.
   PubMedGoogle Scholar
• Buckley PF, Correll CU. 2008. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 69(Suppl 1):4–17.
   Google Scholar
• Cascade E, Kalali AH, Buckley P. 2009. Treatment of schizoaffective disorder. Psychiatry (Edgmont) 6(3):15–17.
   Google Scholar
• Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, et al. Aripiprazole Study Group. 2003. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berlin) 166(4): 391–399.
   PubMed Web of Science ®Google Scholar
• Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, et al. 2013. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 1–10.
   PubMedGoogle Scholar
• Colom F, Vieta E, Daban C, Pacchiarotti I, Sánchez-Moreno J. 2006. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 93(1–3):13–17.
   PubMed Web of Science ®Google Scholar
• Colton CW, Manderscheid RW. 2006. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3:A42.
   PubMedGoogle Scholar
• Correll CU. 2010a. Switching and combining antipsychotics. CNS Spectr 15(4 Suppl 6):8–11.
   PubMed Web of Science ®Google Scholar
• Correll CU. 2010b. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25(Suppl 2):S12–21.
   Google Scholar
• Ereshefsky L, Dugan DJ. 2000. Pharmacodynamic and pharmacokinetic considerations in switching antipsychotic medications. In: Marder SR, editor. Switching antipsychotic medication. London: Science Press Ltd.
   Google Scholar
• Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, et al. 2013. The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry 170(1):1–5.
   PubMed Web of Science ®Google Scholar
• Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, et al. 2010. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35(12):2367–2377.
   PubMed Web of Science ®Google Scholar
• Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ. 2008. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med 6:17.
   PubMedGoogle Scholar
• Grande I, Bernardo M, Bobes J, Saiz-Ruiz J, Álamo C, Vieta E. 2014. Antipsychotic switching in bipolar disorders: a systematic review. Int J Neuropsychopharmacol 17(3):497–507.
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. 2013. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14(3):154–219.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. WFSBP Task force on Treatment Guidelines for Schizophrenia. 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14(1):2–44.
   PubMed Web of Science ®Google Scholar
• Karayal ON, Glue P, Bachinsky M, Stewart M, Chappell P, Kolluri S, et al. 2011. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract 17(2):100–109.
   PubMed Web of Science ®Google Scholar
• Kent S, Fogarty M, Yellowlees P. 1995. Heavy utilization of inpatient and outpatient services in a public mental health service. Psychiatr Serv 46(12):1254–1257.
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, Lee JH, Lee YH, Yang SJ, et al. 2009. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 32(5):243–249.
   PubMed Web of Science ®Google Scholar
• Lee JS, Chung S, Lee JN, Kwon JS, Kim DH, Kim CE, et al. 2010. Efficacy and tolerability of aripiprazole: a 26-week switching study from oral antipsychotics. Psychiatry Investig 7(3):189–195.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE, et al. 2009. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 70(7):990–996.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. 2014. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171(2):160–168.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Scheifler PL, Frances A. 1999. The Expert Consensus Guidelines Series: treatment of schizophrenia. J Clin Psychiatry 60(Suppl 11):1–80.
   Google Scholar
• McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, et al. 2013. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry 74(2):170–179.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. 2005. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 27(12):1930–1941.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535.
   PubMed Web of Science ®Google Scholar
• Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, et al. 2005. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 19(5 Suppl): 22–31.
   PubMed Web of Science ®Google Scholar
• Moteshafi H, Zhornitsky S, Brunelle S, Stip E. 2012. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf 35(10):819–836.
   PubMed Web of Science ®Google Scholar
• Murru A, Pacchiarotti I, Nivoli AM, Grande I, Colom F, Vieta E. 2011a. What we know and what we don't know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol 21(9):680–690.
   PubMed Web of Science ®Google Scholar
• Murru A, Colom F, Nivoli A, Pacchiarotti I, Valenti M, Vieta E. 2011b. When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations. Eur Psychiatry 26(3):183–186.
   PubMed Web of Science ®Google Scholar
• Murru A, Pacchiarotti I, Nivoli AMA, Colom F, Vieta E. 2012a. Is schizoaffective disorder still a neglected condition in scientific literature? [letter] Psychother Psychosom 81(6):389–390.
   PubMed Web of Science ®Google Scholar
• Murru A, Pacchiarotti I, Nivoli AM, Bonnin CM, Patrizi B, Amann B, et al. 2012b. Rates and clinical correlates of treatment non-adherence in schizoaffective bipolar patients. Acta Psychiatr Scand 125(5):412–418.
   PubMed Web of Science ®Google Scholar
• Murru A, Pacchiarotti I, Amann BL, Vieta E, Colom F. 2013. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord 151(3):1003–1008.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. 2014. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo- controlled studies. CNS Spectr. 2014 Jun 23:1–8. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, et al. 2008. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 69(7):1046–1056.
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Weiden PJ, Buchanan RW. 2013. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry 74(11):1108–1120.
   PubMed Web of Science ®Google Scholar
• Nivoli AM, Murru A, Vieta E. 2010. Lithium: still a cornerstone in the long-term treatment in bipolar disorder? Neuropsychobiology 62(1):27–35.
   PubMed Web of Science ®Google Scholar
• Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. 2012. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 22(5):339–346.
   PubMed Web of Science ®Google Scholar
• Popovic D, Torrent C, Goikolea JM, Cruz N, Sánchez-Moreno J, González-Pinto A et al. 2014. Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study. Acta Psychiatr Scand 129(5):366–374.
   PubMed Web of Science ®Google Scholar
• Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, et al. 2010. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71(5):566–573.
   PubMed Web of Science ®Google Scholar
• Richelson E. 2010. New antipsychotic drugs: how do their receptor binding profiles compare? J Clin Psychiatry 71: 1243–1244.
   PubMed Web of Science ®Google Scholar
• Rosa AR, Andreazza AC, Kunz M, Gomes F, Santin A, Sanchez-Moreno J, et al. 2008. Predominant polarity in bipolar disorder: diagnostic implications. J Affect Disord 107(1–3):45–51.
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. 2009. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 107(1):22–29.
   PubMed Web of Science ®Google Scholar
• Roussidis A, Kalkavoura C, Dimelis D, Theodorou A, Ioannidou I, Mellos E, et al. 2013. Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophreniain real-life clinical settings: the ETOS observational study. Ann Gen Psychiatry 12(1):42.
   PubMedGoogle Scholar
• Sajatovic M, Ignacio RV, West JA, Cassidy KA, Safavi R, Kilbourne AM, et al. 2009. Blow FC. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. Compr Psychiatry 50(2):100–107.
   PubMed Web of Science ®Google Scholar
• Scherk H, Pajonk FG, Leucht S. 2007. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 64(4):442–455.
   PubMed Web of Science ®Google Scholar
• Simpson GM, O’Gorman CJ, Loebel A, Yang R. 2008. Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. CNS Spectr 13(10):898–905.
   PubMed Web of Science ®Google Scholar
• Vieta E. 2010. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. J Clin Psychiatry 71(Suppl 2):14–19.
   PubMedGoogle Scholar
• Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, et al. 2012. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes withrisperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 22(11): 825–835.
   PubMed Web of Science ®Google Scholar
• Vieta E, Langosch JM, Figueira ML, Souery D, Blasco-Colmenares E, Medina E, et al. 2013. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int J Neuropsychopharmacol 16(8):1719–1732.
   PubMed Web of Science ®Google Scholar
• Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B; Trial 144 Study Investigators. 2011. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 72(11):1452–1464.
   PubMed Web of Science ®Google Scholar